Keynote 158
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
CLINICALTRIALS.GOV IDENTIFIER:
NCT02628067
When speaking to your doctor, please have the trial identifier number available.
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Dates
Conditions
Advanced Cancer, Advanced Solid Tumors, Anal Cancer, Anal Carcinoma, Bile Duct Cancer, Biliary Cancer, Carcinoid Tumor, Cervical Cancer, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Endometrial Cancer, Endometrial Carcinoma, Mesothelioma, Neuroendocrine Tumor, Parotid Gland Cancer, Salivary Cancer, Salivary Gland Cancer, Salivary Gland Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Thyroid Cancer, Thyroid Carcinoma, Vulvar Cancer, Vulvar Carcinoma
Age Range
18 - No Age Maximum
Sex
All
If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.
Print this page or email it to your doctor to discuss at your next visit.
CLINICALTRIALS.GOV IDENTIFIER:
NCT02628067
When speaking to your doctor, please have the trial identifier number available.
Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.
Print this page
Email this page